Skip to content

Participate in our active studies Subscribe to our Mailing List

AB Science

Masitinib and AB8939 – Two compounds with breakthrough mechanism of action

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Search:

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Corporate Presentation

You are here:

Home
News
2018
Corporate Presentation

13/03/2018 – Current status and perspective for 2018.

Post navigation

PreviousPrevious post:IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to increase the study sample size NextNext post:Defeating the Dakota Access Pipeline at Standing Rock

Related Posts

Update on the restructuring of the AB Science clinical development department in 2018
December 19, 2018

Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment
October 22, 2018

Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis
October 8, 2018

First half of 2018 revenues
October 1, 2018

Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
July 23, 2018

Results of the Combined General Shareholders’ Meeting held on June 29 2018
July 3, 2018

Search

Search:

Recent Posts

Revenues for the first half of 2024 and update on AB Science’s activities
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million euros
AB Science announces a slight delay in the publication of its 2024 half-year financial report
AB Science announces the success of a 5.0 million euros capital increase
AB Science provides an update on the microtubule program AB8939
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

AB SCIENCE
HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

© AB Science – All right reserved